NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis → The last Republican president? (From The Freeport Society) (Ad) Free INCY Stock Alerts $62.69 +2.75 (+4.59%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$59.96▼$62.9650-Day Range$51.18▼$62.6952-Week Range$50.27▼$67.36Volume5.37 million shsAverage Volume4.64 million shsMarket Capitalization$14.08 billionP/E Ratio19.00Dividend YieldN/APrice Target$73.69 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Incyte alerts: Email Address Incyte MarketRank™ Stock AnalysisAnalyst RatingHold2.44 Rating ScoreUpside/Downside17.5% Upside$73.69 Price TargetShort InterestBearish5.19% of Shares Sold ShortDividend StrengthN/ASustainability-2.66Upright™ Environmental ScoreNews Sentiment0.88Based on 17 Articles This WeekInsider TradingSelling Shares$64,389 Sold Last QuarterProj. Earnings Growth26.89%From $3.57 to $4.53 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.59 out of 5 starsMedical Sector75th out of 917 stocksCommercial Physical Research Industry2nd out of 11 stocks 3.2 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 8 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageIncyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.19% of the outstanding shares of Incyte have been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Incyte has recently increased by 54.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 38.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Janus-associated kinase (JAK) inhibitors", "Ponatinib", and "Tafasitamab" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -2.66. Previous Next 3.3 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Incyte this week, compared to 8 articles on an average week.Search Interest13 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows10 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,389.00 in company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 26.89% in the coming year, from $3.57 to $4.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 19.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 19.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.82.Price to Earnings Growth RatioIncyte has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Incyte Stock (NASDAQ:INCY)Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More INCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCY Stock News HeadlinesJune 11 at 5:14 AM | insidertrades.comIncyte Co. (NASDAQ:INCY) Insider Sells $64,388.63 in StockJune 13 at 8:00 AM | businesswire.comIncyte Announces Final Results of Tender OfferJune 12 at 1:26 AM | americanbankingnews.comIncyte Sees Unusually Large Options Volume (NASDAQ:INCY)June 7, 2024 | globenewswire.comMalignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific InterventionsJune 5, 2024 | americanbankingnews.comAnalysts Set Incyte Co. (NASDAQ:INCY) Price Target at $73.69May 30, 2024 | businesswire.comIncyte Completes Acquisition of Escient PharmaceuticalsMay 29, 2024 | finance.yahoo.comSeventh Annual TGaS Advisors Best of Benchmark Award Winners AnnouncedMay 28, 2024 | msn.comIncyte Expands Delaware Presence with New Wilmington BuildingsMay 23, 2024 | msn.comIncyte Moving 300 Chadds Ford Jobs to Wilmington in ExpansionMay 23, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY)May 23, 2024 | markets.businessinsider.com9 Analysts Have This To Say About IncyteMay 22, 2024 | msn.comBiotech firm Incyte is moving 400 workers from Pennsylvania to WilmingtonMay 21, 2024 | bizjournals.comIncyte buys 2 buildings in downtown Wilmington for major expansion, moving 300 jobs from Chadds FordMay 21, 2024 | businesswire.comIncyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office BuildingsMay 16, 2024 | markets.businessinsider.comIncyte’s Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold RatingMay 15, 2024 | msn.comIncyte’s stock rallies 9% after company says to buy back $1.67 billion of its own stock in Dutch auction tenderMay 15, 2024 | wsj.comStocks to Watch Monday: GameStop, AMC, Squarespace, IncyteMay 15, 2024 | forbes.comHow Does Incyte Stock’s Decline During The 2022 Inflation Shock Compare With The 2008 Crash?May 14, 2024 | businesswire.comIncyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressMay 14, 2024 | finance.yahoo.comCompany News For May 14, 2024May 14, 2024 | marketwatch.comStock Market Today: Dow snaps 8-day winnning streakMay 14, 2024 | finance.yahoo.comHeard on the Street Monday Recap: Hello KittyMay 14, 2024 | benzinga.comGameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On MondayMay 14, 2024 | marketwatch.comIncyte Shares Rally on $2 Billion Buyback PlansMay 14, 2024 | msn.comIncyte Stock Marks Biggest Jump in 7 Years on ‘Dutch Auction’ Buyback Plan. How It Works.See More Headlines Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today6/14/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,524Year Founded1991Price Target and Rating Average Stock Price Target$73.69 High Stock Price Target$93.00 Low Stock Price Target$52.00 Potential Upside/Downside+17.5%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$3.30 Trailing P/E Ratio19.00 Forward P/E Ratio17.56 P/E Growth1.28Net Income$597.60 million Net Margins19.78% Pretax Margin27.03% Return on Equity12.83% Return on Assets9.80% Debt Debt-to-Equity Ratio0.01 Current Ratio3.47 Quick Ratio3.43 Sales & Book Value Annual Sales$3.77 billion Price / Sales3.74 Cash Flow$2.57 per share Price / Cash Flow24.40 Book Value$23.16 per share Price / Book2.71Miscellaneous Outstanding Shares224,541,000Free Float185,246,000Market Cap$14.08 billion OptionableOptionable Beta0.74 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Herve Hoppenot (Age 64)CEO & Chairman Comp: $2.9MDr. Pablo J. Cagnoni M.D. (Age 61)Ph.D., President and Head of Research & Development Comp: $2.03MMs. Christiana Stamoulis MBA (Age 53)Executive VP & CFO Comp: $1.18MDr. Barry P. Flannelly M.B.A. (Age 66)Pharm.D., Executive VP & GM of North America Comp: $1.01MDr. Steven H. Stein M.D. (Age 57)Executive VP & Chief Medical Officer Comp: $1.32MMr. Thomas Tray (Age 46)VP of Finance, Chief Accounting Officer & Controller Mr. Michael James Morrissey (Age 60)Executive VP & Head of Global Technical Operations Mr. Ben StrainHead of Investor RelationsSheila A. Denton (Age 58)Executive VP, General Counsel & Corporate Secretary Ms. Pamela M. Murphy (Age 73)Vice President of Investor Relations & Corporate Communications More ExecutivesKey CompetitorsMedpaceNASDAQ:MEDPCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHPPDNASDAQ:PPDSyneos HealthNASDAQ:SYNHView All CompetitorsInsiders & InstitutionsThomas TraySold 1,093 sharesTotal: $64,388.63 ($58.91/share)DekaBank Deutsche GirozentraleBought 24,328 shares on 6/4/2024Ownership: 0.068%Teachers Retirement System of The State of KentuckySold 807 shares on 5/28/2024Ownership: 0.007%Cetera Advisors LLCBought 4,225 shares on 5/24/2024Ownership: 0.002%Swedbank ABBought 657,193 shares on 5/21/2024Ownership: 0.293%View All Insider TransactionsView All Institutional Transactions INCY Stock Analysis - Frequently Asked Questions Should I buy or sell Incyte stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. View INCY analyst ratings or view top-rated stocks. What is Incyte's stock price target for 2024? 18 brokerages have issued 1 year price objectives for Incyte's shares. Their INCY share price targets range from $52.00 to $93.00. On average, they anticipate the company's stock price to reach $73.69 in the next year. This suggests a possible upside of 17.5% from the stock's current price. View analysts price targets for INCY or view top-rated stocks among Wall Street analysts. How have INCY shares performed in 2024? Incyte's stock was trading at $62.79 on January 1st, 2024. Since then, INCY shares have decreased by 0.2% and is now trading at $62.69. View the best growth stocks for 2024 here. Are investors shorting Incyte? Incyte saw a increase in short interest in May. As of May 31st, there was short interest totaling 11,660,000 shares, an increase of 54.6% from the May 15th total of 7,540,000 shares. Based on an average daily trading volume, of 2,820,000 shares, the days-to-cover ratio is currently 4.1 days. View Incyte's Short Interest. When is Incyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our INCY earnings forecast. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) released its earnings results on Tuesday, April, 30th. The biopharmaceutical company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.69 by $0.31. The biopharmaceutical company had revenue of $880.89 million for the quarter, compared to the consensus estimate of $935.85 million. Incyte had a trailing twelve-month return on equity of 12.83% and a net margin of 19.78%. What ETFs hold Incyte's stock? ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), Bushido Capital US Equity ETF (SMRI), IQ U.S. Mid Cap R&D Leaders ETF (MRND), ASYMshares ASYMmetric S&P 500 ETF (ASPY), VanEck Biotech ETF (BBH) and First Trust Health Care AlphaDEX Fund (FXH). What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA). Who are Incyte's major shareholders? Incyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (16.11%), Vanguard Group Inc. (10.12%), Acadian Asset Management LLC (1.24%), LSV Asset Management (1.23%), Jacobs Levy Equity Management Inc. (1.12%) and Bellevue Group AG (0.96%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INCY) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.